Author

K. T. Flaherty

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 3 Organism:human· 3 Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

G. M. Boland· 4 shared A. Mehta· 3 shared D. Liu· 3 shared D. T. Frederick· 3 shared R. J. Sullivan· 3 shared J. Park· 2 shared K. Yizhak· 2 shared M. Kellis· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

G. M. Boland

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Genomic heterogeneity and ploidy identify patients with intrinsic resistance to PD-1 blockade in metastatic melanoma

G. Tarantino, C. A. Ricker, A. Wang, W. Ge, T. J. Aprati, A. Y. Huang, S. Madha, J. Chen, Y. Shi, M. Glettig, D. T. Frederick, S. Freeman, M. M. Holovatska, M. P. Manos, L. Zimmer, , D. Liu

This study identifies genomic heterogeneity and ploidy as markers of intrinsic resistance to PD-1 blockade in metastatic melanoma, with a decision tree model predicting resistance with high confidence.

Science Advances · Nov 29, 2024Peer-reviewedCancer Biology

Disrupting CD38-driven T cell dysfunction restores sensitivity to cancer immunotherapy

O.-Y. Revach, A. M. Cicerchia, O. Shorer, B. Petrova, S. Anderson, J. Park, L. Chen, A. Mehta, S. J. Wright, N. McNamee, A. Tal-Mason, G. Cattaneo, P. Tiwari, H. Xie, J. M. Sweere, , K. Yizhak

This study shows that targeting CD38 improves T cell function and restores response to immunotherapy in melanoma models.

bioRxiv · Feb 12, 2024 · PreprintCancer Biology

Plasma proteomic biomarkers identify non-responders and reveal biological insights about the tumor microenvironment in melanoma patients after PD1 blockade

A. Mehta, M. Rucevic, E. Sprecher, M. Parikh, J. Chem, D. T. Frederick, E. Woods, L. Bi, D. Lieb, L. Hultin-Rosenberg, J. Guess, R. J. Park, A. Schneider, W. Michaud, B. Miao, , G. M. Boland

The paper identifies plasma proteomic biomarkers that predict non-response to PD1 blockade in melanoma patients and links them to tumor microenvironment biology.

bioRxiv · Feb 2, 2022 · PreprintCancer Biology

Plasma-derived exosomal analysis and deconvolution enables prediction and tracking of melanoma checkpoint blockade response

A. Shi, G. G. Kasumova, W. A. Michaud, J. Cintolo-Gonzalez, J. F. Ohmura, A. Mehta, I. Chien, D. T. Frederick, S. Cohen, D. Plana, D. Johnson, K. T. Flaherty, R. J. Sullivan, M. Kellis, G. M. Boland

This paper uses plasma-derived exosomal RNA to predict and track melanoma response to immune checkpoint inhibitors by analyzing tumor and immune signatures.

bioRxiv · Oct 18, 2019 · PreprintCancer Biology